Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I await his response too but by no means do I blame him for me staying in this until the end. I am always an optimist and whether I sell and take my loss or wait for it to go up again, which it will is all on me.
Appreciate your sympathy govprs. I don't care what the others say, you're a top fellow/girl.
Ouch, well, you win some and lose some. In the words of Jim Morrison, "This is the end." The hope of a big pay day is gone. The best you can hope for is a buyout and that probably will take a while. Probably time to sell, lick your wounds and take a loss, move on....
The pump and dump has materialized but who pays? Sorry for most of you here
“The Company believes that once it has completed the evaluation of the Study’s data, it could support further discussions with the FDA on potential new clinical studies and allow the opportunity to work with potential domestic and international pharmaceutical partners to determine a suitable regulatory pathway for approval of Bucillamine based on the evaluated Study’s data.”
This study is done and a wash apparently. Only way forward is a partner and new clinical trials for a “suitable regulatory pathway” which we all know how long will take. The fat lady has sung. How low does it go today? .2? .1? 0?
The DSMB recommended that the Study be halted early due to statistical significance of the primary endpoint likely not going to be met should the Study continue towards completion. Based on the recommendation from the DSMB, the Company has halted the Study and will now proceed to unblind and seek an evaluation of the Study’s data, including the COVID-19 clinical symptoms data (i.e. cough, fever, heart rate, and oxygen saturation) to determine the potential next clinical and regulatory steps for Bucillamine.
News out. The fly speaks...
https://www.stocktitan.net/news/RVVTF/revive-therapeutics-provides-update-of-phase-3-clinical-study-for-3x0it6c60rx7.html
ps. Endpoints suck. We knew that... More unblinding? What did they look at? Confused at the moment.
If only we knew what that darned fly knows!
Without partnerships this is toast. Why it took MF years to conclude that explains why this sits at a nickel.
GLTA
If I am not mistaken MF in his last comments mentioned partnership more than once. GLTA!!
They raise 4mil at .15 valuation what a joke
Nobody was stopping anything when viewing 210 patients. With the addition of 500 dosed at higher levels of Buccy, and a surge in covid cases, one can hope that it's zero for buccy and nine for the placebo. That's all. You can't blame a guy for hoping and believing. With capital running out, Revive needs a partnership and the only way to that agreement is solid data.
ps. GLTA
You do realize if that were the case they would have halted the trial 2 years ago to look at the data. Best case is placebo had a few hospitalizations and bucc had none.
That is my understanding, although Revive doesn't own the rights to Buccy in a few places in Asia, but, I believe, the rest of the world is fair game.
ps. We wait.
On good data would they be able to continue the study with new EP’s for FDA purposes while simultaneously marketing and selling it outside the US for immediate use in those countries that allow it?
I tend to agree with everything you stated, but the hail mary pass is that Buccy had no hospitalizations and the placebo group had eleven.
don't get too anxious - if they decide to continue the study, they'll probably need to still get an infusion from a partnership; change end points and start over. If they decide to stop the study they'll need an infusion from a partnership and restart a study with different / changed endpoints. Even if they say it's the greatest thing since sliced bread the endpoints are antiquated so they'll need an infusion from a partnership and restart a new study with different endpoints. I don't think with the current endpoints that the FDA will be impressed. The study just took too darn long with those endpoints.
Was MF in a good mood this evening? Did he play golf, smoke a stogie, etc. ? Rubber, where is that fly on the wall?
I'm looking for volume of 500,000 tomorrow.
ps. We will know soon enough, likely within seven days.
Hopefully the the outcome will have been well worth the wait.
GLTA!
Looking forward to the return of friends!
Cw,
I liked this post in stock wits hope he is right , heck I don't know about this stuff...
https://stocktwits.com/BaronXXII/message/526985259
copy pasted here...DSMB review should kick off with an "open" session where RVVTF may be present (to answer questions, frame the report, etc.)
They can then move to a closed session to discuss data. A possible separate executive session (dsmb voting members only) to vote.
If anyone outside RVVTF attends the open session (silent partner?) word would likely spread swiftly. Watch for volume tomorrow.
(Yes. I know it's more realistic that that any silent partner would just wait until the dsmb answer before "doing" anything.)
ps. better if I mute the dummy here from stockwits who does not know me at all lol....
And Covid is far from Over hardly any testing now,test not working on new variants etc..
Of course it’s covid https://t.co/b5UE9sg9Ty
— Chris Turnbull (@EnemyInAState) May 8, 2023
Dear Experts:
— Marvin (@MarvinH2_G2) May 9, 2023
Blue is seasonal
Red is not seasonal https://t.co/O9E1zExEYH
Maybe he wasn't and isn't so interested in pursuing a sales product in support of the covid biosphere. .
Thank you Senor! Look forward to it!
D!¢$ are swinging in the. no pun intended. lol
Checking in and nice to see everyone still around,lets get some good data and a buyout offer,we didnt wait all this time
for nothing.
Allow me to be the first to kick off the festivities for tomorrow. MF will be schmoozing in the morning with the DSMB to get this product to market in the states. After analyzing the amazing data, there will be a slight leak as volume mounts in the afternoon. Within one week, MF drops a press release with the results of the trial. If Revive continues the trial with a partner, so be it. If they get bought out, good. If the trial was a flop, it is an expensive lesson and a few more years of hard work.
ps. Yes. I am the king of $2 lunches, Gator.
pps. I expect to hear from Rubber, Blue, All, Cool, Eco, Gator, Nosnibor and others as we start getting psyched up for the results of the 720 patients. One episode will certainly end within a week. Will another begin? It's anyone's guess. GLTA. (even Snoopy)
Been super busy, thanks for asking. Been doing the stealth possum thing, and the fox thing, hunting and been research a lot of over lapping health-bio-chemistry research and helping the world solve a food problem can cattle feed problem. And watching some new Netflix shows while we wait for $RVVTF major off to the Moon rally news. I do read & scan posts here....
"Averaging Down" is a common tool investors use that gets them into trouble after falling in love with their investments. WE have all been victims of that.
My question is --- if the trial is a failure, will the pps fall further. Or is failure already baked into the current price.
I've always felt that the CEO had fallen in love with his shrooms, and never really gave much priority to Bucillamine as a covid therapy. He had plenty of time to prepare for an FDA green light to proceed, and instead he dragged his feet early on. He did not have his ducks in a row for launching a covid trial. That was my red flag. And the FDA is no longer under pressure to approve EUA applications for covid. Slow you blow, snooze you loose.
Bullshite
The most apt response for that insipid garbage.
Why would someone waste their time posting stupid conspiracy theories and nonsense speculation on a stock they do like?
Sunk Cost Fallacy perfectly sums up this message board in three words. Perhaps you shouldn't have doubled and tripled down on it. But hey, we all screw up from time to time.
All I can say is Lol.....
why would someone waste there time posting stupid chit on a stock they dont like, managment probably more so ...in the stock forums that they do not like Lmao......
Get a fck ing life! :)
Poor little Gatorca. You've been wrong every step of the way. You and assic Warrior...wrong 100% of the time. Maybe it's time for the two of you to come clean with the six people left on the message board. Giovanni too. You guys are a true threesome. Rub-a-dub-dub three men in a tub!
Jack long covid complications will be with us forever. If buci can be used as a treatment so be it.
My stories lol your wacked out where the f uck u see that:)
By the way lol. Bmt know the Chit works but will the company show the best possible data lol...
ps, no your a washed up piece of chit lol.....
Gio,
All I can say is wtf lol...
I can't think of a more idiotic headline. Seriously. The freaking Center for Disease Control needs to open a probe into why a bunch of their infectious disease "experts" were infected by an incredibly transmissable respiratory virus while crowded together indoors maskless? 🤡💩💀 pic.twitter.com/cTorBNiQXu
— David Christopher 🏥🥼 🇵🇸 (@MLS_Dave) May 2, 2023
So that's what it's come to. Believers and nonbelievers.
Correct me if I'm wrong but isn't that what happens when you're close to the bottom?
I've had Covid once, for two weeks in the first half of October 2022. It came with conjunctivitis.
Alex- I'll take Bucillamine for $.20.
ps. Now Alex is gone.
pps. It was easier to laugh back then.
ppps. Good luck to all. (even Snoopy)
Sometime seems forever lol Cw :)
But anyways sure you seen this but chit I would be very happy even with 1B even.
Bucillamine Phase 3 clinical trial (NCT04504734) for #COVID-19 💊
— BITCOIN | DATA | LONG COVID (@kamtraders) May 4, 2023
By Revive Therapeutics $RVV $RVVTF
▪️DSMB meeting on May 10th, 2023 and will assess the efficacy of Bucillamine
▪️Revive expects to announce the recommendation of the DSMB meeting by May 17th, 2023.$veru $pfe pic.twitter.com/sP6M9RSec7
It will be nice to finally see the results after all this waiting and speculation. Good or bad, either way I can move on.
May 17th can not come soon enough. There is no excitement, based on the pps, as the longs hold and the rest of the world remains nonbelievers.
ps.It will be nice to finally see the results of the patients who took the higher dosage of Buccy. We have been waiting for quite some time.
A significant amount of asymptomatic Covid infections result in #LongCovid.
https://twitter.com/JacobBAguilar/status/1653916482655453185
ps. not sure why he follow me lol
pps. wait Cw ok he follows about %50 :) lol
Olympic gold medalist Tori Bowie dies aged 32. Just saying The BusS is moving. You will require it for the remainder of your lifetime. Or you GET SIDS
https://www.cnn.com/2023/05/03/sport/tori-bowie-death-track-and-field-spt-intl/index.html
What to know about XBB.1.16, the 'Arcturus' variant
A new Covid variant is spreading in the U.S., but will it cause a surge in cases?
XBB.1.16 — dubbed “Arcturus” on social media — is another descendant of omicron. It was first detected in early January and the majority of cases have been seen in India so far. It’s been steadily rising in the U.S. in recent weeks, although it still made up slightly less than 10% of new confirmed Covid cases as of Saturday, according to the Centers for Disease Control and Prevention.
Last week, the World Health Organization deemed XBB.1.16 a “variant of interest” as it continues to spread and outcompete other variants.
Ali Mokdad, a professor of global health at the University of Washington, said it’s still too early to predict what XBB.1.16 will do. But what he’s seen so far has been reassuring.
“We haven’t seen an increase in hospitalizations, we haven’t seen an increase in any of the indicators that make us worry,” Mokdad said.
Is XBB.1.16 more contagious?
Mokdad said that XBB.1.16 is gaining ground on the previously dominant strain in the U.S., called XBB.1.5.
That increased transmissibility appears to be due to the subvariant’s ability to avoid immune detection in the body.
“It can’t be spreading so fast unless it has some immune escape,” Mokdad said.
The virus has two ways of surviving, Mokdad said. One way is to be more infectious and evade immunity from previous infections or vaccinations, “which this one is doing,” he said. The other one is to become really deadly. “We haven’t seen that yet.”
Dr. Peter Chin-Hong, a professor of infectious disease at the University of California, San Francisco, said that aside from the increase in transmissibility, so far XBB.1.16 is not too different from XBB.1.5.
That means that “hopefully, it’s not going to be too different” in terms of how sick it makes people and how well the vaccines work.
What are the symptoms of XBB.1.16?
XBB.1.16 doesn’t appear to be making people sicker than earlier omicron strains, according to Dr. Mike Ryan, the executive director of the WHO’s health emergencies program.
“To my knowledge, we’re not seeing a different spectrum of symptoms or severity associated with this variant of interest,” Ryan said during a media briefing last week.
Some news reports have mentioned that XBB.1.16 infection causes a “new” symptom — conjunctivitis, or pink eye — though the WHO noted that this symptom was already known to be associated with Covid. As early as the spring of 2020 there were reports of itchy, sore eyes in Covid patients. In May 2020, the American Academy of Ophthalmologists noted that mild conjunctivitis could be a symptom of Covid.
"It's not a new symptom," but it may be more common than previously thought, Chin-Hong said.
Do vaccines work against XBB.1.16?
Mokdad said that labs haven’t yet determined how well the Covid vaccines work against XBB.1.16.
Chin-Hong said he wasn't particularly concerned about the vaccines.
"Because it's so similar to XBB.1.5, we think that vaccines will be fine," he said.
Last week, the Food and Drug Administration and the CDC said that older adults and immunocompromised individuals could get a second dose of the updated booster shot, which protects against an earlier omicron subvariant.
Why are there always new variants?
XBB.1.16 certainly won’t be the last new variant that emerges. The subvariant is yet another offshoot of the growing omicron family tree.
XBB.1.16 is a descendant of the XBB subvariant, which itself formed when two strains of omicron subvariant BA.2 combined, according to the WHO.
Already, two other XBB strains, XBB.1.9.1 and XBB.1.9.2 are also rising in the U.S. Together, the two strains account for about 11% of new cases, according to the CDC.
On Wednesday, the WHO's technical lead for Covid-19, Dr. Maria Van Kerkhove, said the XBB.1.9 strains are likely similar to what’s been seen with previous XBBs.
“This just indicates to us that the virus continues to evolve and it will continue to evolve because the virus is circulating pretty much unchecked,” Van Kerkhove said.
nbcnews.com
Ecomike
Whiners are in general losers!
RVVTF is for winners.??
Followers
|
337
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
36642
|
Created
|
02/23/17
|
Type
|
Free
|
Moderators Classic Warrior |
Scientific Rationale of Bucillamine
Preclinical and clinical studies have demonstrated that reactive oxygen species contribute to the destruction and programmed cell death of pulmonary epithelial cells.1 N-acetyl-cysteine (NAC) has been shown to significantly attenuate clinical symptoms in respiratory viral infections in animals and humans, primarily via donation of thiols to restore antioxidant and to reduce the activity of cellular glutathione 2,3,4,5. Bucillamine (N-(mercapto-2-methylpropionyl)-l-cysteine) has a well-known safety profile and is prescribed in the treatment of rheumatoid arthritis in Japan and South Korea for over 30 years. Bucillamine, a cysteine derivative with two thiol groups, has been shown to be 16 times more potent as a thiol donor in vivo than NAC 6. The drug is non-toxic with high cellular permeability. The basis of the clinical study will analyze if Bucillamine has the potential, via restoration of glutathione activity and other anti-inflammatory activity, to lessen the negative consequences of SARS-CoV2 infection in the lungs.
| Psilocin Pharma Corp. has developed production solutions for the active compound Psilocybin. Our process encompassed with our intellectual property cover methods of production of Psilocybin based formulations. Psilocin Pharma Corp’s range of products have been engineered to work synergistically with the body's own natural pathways of absorption while offering a contemporary approach to consumption. Psilocin Pharma also has strong relationships with specific lab partners in certain areas like Brazil, where these formulations are legally approved and plan to sell products in these jurisdictions. | |
| |
Mental Health (Depression, PTSD & Anxiety)
|
Supplements for Brain Health & Cognitive Enhancement
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |